SURMODICS INC (SRDX)

SRDX Stock Earnings: Surmodics Beats EPS, Beats Revenue for Q2 2024

SRDX stock results show that Surmodics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

Surmodics Enters Oversold Territory (SRDX)

Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1

Surmodics is Now Oversold (SRDX)

Surmodics to Participate in Upcoming Investor Conferences in March and April

Surmodics is Now Oversold (SRDX)

Surmodics (SRDX) Shares Cross Below 200 DMA

Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee

Surmodics to Host Virtual Annual Meeting of Shareholders

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium

Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium

Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28

(NASDAQ:SRDX)

Surmodics reports Q4 non-GAAP EPS of $0.53 and revenue of $28M, marking a 7.8% year-over-year increase.

Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance

Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium

Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15

Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications

Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8

Commit To Purchase Surmodics At $30, Earn 16% Annualized Using Options

Surmodics is Now Oversold (SRDX)

Surmodics to Participate in Upcoming Investor Conferences in August

(NASDAQ:SRDX)

Surmodics press release (SRDX): Q3 Non-GAAP EPS of $0.52 beats by $0.98.Revenue of $52.5M (+110.8% Y/Y) beats by $14.44M.

Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2

Why Shares of Surmodics Jumped This Week

The company gained FDA marketing approval for a drug-coated balloon that will help clear blocked arteries.

Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon

Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System